TCF7L2 and colorectal carcinoma: Silencing CASC9 can not only downregulate AKT3 expression by reducing the competitive binding of CASC9 with miR-576-5p, thereby inhibiting CRC cell proliferation (210), it can also inhibit the proliferation of CRC cells through the miR-542-3p/integrin-linked kinase pathway (80), CCAT2 is highly overexpressed in microsatellite stable CRC and can enhance tumor growth by activating the WNT signaling pathway through the CCAT2/miR-17-5p/TCF7L2 axis (86).